Expanded Role of BRCA Testing and Adjuvant PARP Inhibition in Early Breast Cancer

  • In the OlympiA trial, adjuvant therapy with olaparib vs placebo demonstrated a benefit in overall survival, invasive disease‒free survival, and distant disease‒free survival in eligible patients with early breast cancer and gBRCApathogenic variants.
  • With the expanded role of BRCAtesting in early breast cancer, completion of testing in eligible patients is critical.
  • Given the survival benefit of adjuvant PARP inhibition in this population, patient and healthcare professional education on the importance of genetic testing and benefits of therapy is key.
#Arrangoiz #BreastSurgeon

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s